Pollinex Quattro Tree: Allergy vaccine

Asthma & Allergy Research Associates, President's Drive, Upland, PA 19013, USA.
Expert opinion on biological therapy (Impact Factor: 3.74). 04/2009; 9(3):377-82. DOI: 10.1517/14712590802699596
Source: PubMed


An overview of short-term specific immunotherapy (ST-SIT) highlighting Pollinex Quattro (PQ) Tree is presented. The product development of this novel allergy vaccine using modifying agent glutaraldehyde, adjuvant monophosphoryl lipid and L-tyrosine have heralded a superior ST-SIT. Since 1999 when PQ was founded in Germany, various research trials assessing both the standardization and clinical studies have been done. A review of these studies demonstrates the efficacy and safety of PQ Tree in both pediatric and adult trials. The uniqueness of this product allows a shorter course of four pre-seasonal injections to provide control of allergy symptomatology in seasonal rhinitis patients. The PQ Tree product studies show a similar efficacy and safety profile to the grass formulation trial.

19 Reads
  • Source
    • "Little is known, however, about the vaccine’s efficacy in treating asthma. Despite the clinical advantages of this product,9 the immunological changes following treatment have not been fully elucidated. In addition, the changes induced by the MPL-adjuvated vaccine on lower airway inflammation are not clear. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The ultra-short course pre-seasonal allergy vaccine, containing appropriate allergoids with the adjuvant monophosphoryl lipid A (MPL), may be effective in treating allergic symptoms. To explore the timing of the immunological responses to the pre-seasonal allergy vaccine. Four subcutaneous injections of the active product (Pollinex Quattro) were administered to 20 Parietaria-sensitive intermittent asthmatics (M/F: 12/8; age: 48 ± 10 years; FEV(1)% predicted: 108% ± 12%) during the 6 weeks prior to the start of the pollen season. Exhaled breath condensate (EBC) was collected immediately before the first and immediately after the last injections (t(1) and t(2)), during the pollen season (t(3)) and after (t(4)) the pollen season. EBC was analyzed to determine the levels of pH and 8-isoprostane. Ten Parietaria-sensitive asthmatics served as the untreated control group at t(1) and t(2). Measured pH levels were 7.64 ± 0.33 at t(1), 7.67 ± 0.23 at t(2), 7.72 ± 0.34 at t(3), and 7.82 ± 0.34 at t(4) (P = 0.049 vs baseline). 8-isoprostane levels were significantly lower than baseline at each visit (mean difference from baseline, for t(2): -0.77 pg, P = 0.031; for t(3): -0.92 pg, P = 0.010; for t(4): -0.70 pg, P = 0.048). In the control group, pH levels were 7.73 ± 0.26 at baseline and did not change after 6 weeks (7.79 ± 0.25, P = 0.33). Similarly, the concentrations of 8-isoprostane in the control group were not different from those of the study group at baseline (P = 0.86), and the levels remained unchanged after 6 weeks (P = 0.58). These findings show that the ultra-short course of vaccine adjuvated with MPL acutely reduces the degree of airway inflammation, as expressed by markers of oxidative stress, and suggest that this reduction is maintained during and after the pollen season.
    Journal of Asthma and Allergy 03/2011; 4:19-25. DOI:10.2147/JAA.S17784
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This article reviews the literature on allergen modifications and novel routes of delivery for antigen-specific immunotherapy for allergic disease. Allergen modifications include the use of recombinant proteins, combining antigens with infectious carrier proteins, peptide immunotherapy, and genetic vaccines containing the code for allergenic proteins. Novel routes of delivery include oral immunotherapy, intralymphatic immunotherapy, epicutaneous immunotherapy, and oral mucosal immunotherapy. Allergen depot preparations, such as biodegradable, injectable microspheres and sublingual tablets, have also been developed. Current research in immunotherapy for allergic disease has focused on improving efficacy and patient adherence to therapy, while minimizing the risks of serious adverse events.
    06/2013; 1(2). DOI:10.1007/s40136-013-0009-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Worldwide population affected by allergic rhinitis and asthma are estimated to 400 million and 300 million respectively, and the medical costs for treatment are estimated to exceed that of tuberculosis and AIDS allied. The main objective of this research is to propose a vaccine design strategy for the management of allergy through siRNA vaccination in silencing IgE VH region. The allergen Che a 3 was chosen to demonstrate our approach. Docking interactions between Che a 3 and modeled structures of heavy chain variable region of 31 Immunoglobulin E clones were analyzed in AutoDock. Concurrently, small interference RNA sequences targeting the Immunoglobulin E clone with least binding energy were designed in siDRM. KeywordsAllergy-Asthma-Immunoglobulin E-Vaccine-Immunotherapy-Small interference RNA-AutoDock-Bioinformatics-Docking- In silico
    12/2009: pages 193-207;
Show more